Floatz logo

Allogeneic Natural Killer Cells

Microsatellite Instability

Fate TherapeuticsCell therapyDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Microsatellite Instability cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Fate Therapeutics
Phase 2B
Nivolumab
Fate Therapeutics
Phase 2B
Atezolizumab
Fate Therapeutics
Phase 2B
Cyclophosphamide
Udai Kammula
Phase 2B
Fludarabine
Udai Kammula
Phase 2B

View all 14 →

Same molecule, other indications

Allogeneic Natural Killer Cells is also rated in:

primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
44 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →